The EMA recommends approval of Biofrontera's BF-200 ALA
Advertisement
The European Medicines Agency (EMA) issued a favourable opinion on Biofrontera's marketing approval application for its new medicinal product BF-200 ALA for the treatment of actinic keratosis. There was no recommendation for a restriction or temporal limitation of the approval. The product will be marketed under the name Ameluz®. The positive assessment report on the product, generated by the responsible committee within the EMA, the Committee for Medicinal Products for Human Use (CHMP), will now be forwarded to the European Commission for the formal conclusion of the process. Before the marketing approval will be issued, anticipated in December, the product information will be translated into all languages of the European Union and attuned with the respective local health agencies. Following approval, Ameluz® can be commercialized in all 27 countries of the EU as well as Norway, Island and Liechtenstein.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Acambis concludes C. difficile vaccine formulation work on schedule and will commence proof-of-concept trial in 2008
Sosei Announces Agreement With Mundipharma For Ad 923
SoluBest and Dr. Reddy´s Sign Drug Delivery Collaboration to Develop New, Proprietary Formulations
Clavis Pharma appoints Nicholas Adams as Chief Business Officer
Acambis' universal influenza vaccine enters Phase 1 trial
LGC Genomics and Bioplant R& D sequence the transcriptome of Jatropha curcas
Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
Scil Proteins acquires Tat Phage display from ipal GmbH and Charité